NCT06504901View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab 200mg ivd D1

DRUG

Interleukin-2

Interleukin 2 100IU HD,QOD d1-d14

DRUG

Capecitabine

Capecitabine: 1000mg/m2 bid po, d1-d14

DRUG

Oxaliplatin

Oxaliplatin 130mg/m2 ivd, d1

DRUG

Neupogen

rhG-CSF 5mcg/kg HD, QD d1-d14

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06504901 - Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases | Biotech Hunter | Biotech Hunter